Kacie L. Beatch, Ph.D.
Senior Program Manager
Kacie joined Cognigen in May 2020 as Senior Program Manager. She holds a Bachelor of Science degree in Clinical Laboratory Science and a PhD in Pharmaceutical Sciences from North Dakota State University. After a two-year post-doctoral fellowship in Clinical Research, she spent seven years as a Clinical Research Scientist with focus on Phase 1 and generic drug development—contributing to over 40 product development programs and at least two dozen approved FDA submissions. Kacie is a member of the American Association of Pharmaceutical Scientists, the American Society of Clinical Pharmacology and Therapeutics, and maintains her certification as a Medical Laboratory Scientist under the American Society of Clinical Pathology.
Simulations Plus' data processing agreement for distributors, resellers, and service providers.
Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist/antagonist being investigated in patients with negative symptoms of schizophrenia. This analysis aimed to characterize exposure-response relationships of...
OC-001 is a CD137 mAb agonist designed to show differential agonistic activity from that of competitor
antibodies. OC-001 provided T cell activation that
Dr. Brian P. Booth and Dr. Hao Zhu from the Office of Clinical Pharmacology (OCP) at the FDA will present and discuss Project Optimus, an initiative from the Oncology Center of Excellence (OCE) to reform the dose optimization and dose selection paradigm in oncology drug development.